JESÚS
RUIZ CONTRERAS
Ikertzailea 2022-(e)ra arte
GlaxoSmithKline (Spain)
Madrid, EspañaGlaxoSmithKline (Spain)-ko ikertzaileekin lankidetzan egindako argitalpenak (4)
2008
-
Immunogenicity and reactogenicity of a booster dose of a novel combined haemophilus influenzae type b-neisseria meningitidis serogroup c-tetanus toxoid conjugate vaccine given to toddlers of 13-14 months of age with antibody persistence up to 31 months of age
Pediatric Infectious Disease Journal, Vol. 27, Núm. 7, pp. 579-588
2007
-
Immunogenicity and reactogenicity of primary immunization with a novel combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine coadministered with a diphtheria-tetanus- acellular pertussis-hepatitis B-inactivated poliovirus vaccine at 2, 4 and 6 months
Pediatric Infectious Disease Journal, Vol. 26, Núm. 1, pp. 1-7
2006
-
Immunogenicity and reactogenicity of primary immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type B vaccine coadministered with two doses of a meningococcal C-tetanus toxoid conjugate vaccine
Pediatric Infectious Disease Journal, Vol. 25, Núm. 8, pp. 713-720
2003
-
Epidemiology and economic impact of varicella in immunocompetent children in Spain. A nation-wide study
Vaccine, Vol. 21, Núm. 23, pp. 3236-3239